Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix

Ota,Yukihide; Koizume,Shiro; Nakamura,Yoshiyasu; Yoshihara,Mitsuyo; Takahashi,Tomoko; Sato,Shinya; Myoba,Shohei; Ohtake,Norihisa; Kato,Hisamori; Yokose,Tomoyuki; Miyagi,Etsuko; Miyagi,Yohei

doi:10.3892/or.2021.7944

Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix

Authors:
- Yukihide Ota
- Shiro Koizume
- Yoshiyasu Nakamura
- Mitsuyo Yoshihara
- Tomoko Takahashi
- Shinya Sato
- Shohei Myoba
- Norihisa Ohtake
- Hisamori Kato
- Tomoyuki Yokose
- Etsuko Miyagi
- Yohei Miyagi
View Affiliations

Affiliations: Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama 241‑8515, Japan, Bioscience Division, Reagent Development Department, Tosoh Corporation, Ayase, Kanagawa 252‑1123, Japan, Department of Gynecologic Oncology, Kanagawa Cancer Center, Yokohama 241‑8515, Japan, Department of Pathology, Kanagawa Cancer Center, Yokohama 241‑8515, Japan, Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine, Yokohama 236‑0004, Japan
Published online on: January 20, 2021 https://doi.org/10.3892/or.2021.7944
Pages: 1023-1032
Copyright: © Ota et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tissue factor pathway inhibitor‑2 (TFPI‑2) is a promising candidate as a serum biomarker of ovarian clear cell carcinoma (OCCC), a lethal histological subtype of epithelial ovarian cancer (EOC). TFPI‑2 is a secreted serine protease inhibitor that suppresses cancer progression through the inhibition of matrix protease activities. Previous studies have also identified TFPI‑2 in the nucleus, and a possible function of nuclear TFPI‑2 as a transcriptional repressor of matrix metalloproteinase‑2 (MMP‑2) was recently demonstrated. We are currently establishing TFPI‑2 as a serum biomarker for OCCC patients; however, TFPI‑2 expression in OCCC tissues has not been previously investigated. In the present study, we examined TFPI‑2 expression and its localization in 11 OCCC cell lines by western blotting and enzyme‑linked immune assay. Four cell lines expressed TFPI‑2 in the nucleus, cytoplasm and culture plate–attached extracellular fraction, while four other cell lines expressed TFPI‑2 only in the extracellular fraction. In the remaining three cell lines, TFPI‑2 was not identified in any fraction. The amount of secreted soluble TFPI‑2 showed similar trends to that of the plate‑attached fraction. We next investigated the expression levels and distribution of TFPI‑2 in surgically resected EOC tissues by immunohistochemistry. In 52 of the 77 (67.5%) OCCC tumors, TFPI‑2 expression was detected in at least one of the nuclear, cytoplasmic and extracellular matrix fractions. In contrast, we did not identify TFPI‑2 in the other EOC subtypes (n=65). TFPI‑2‑positive expression distinguished CCC from the other EOC tissues with a sensitivity of 67.5% and specificity of 100%. Although the inherent tumor suppressor function, statistical analyses failed to demonstrate correlations between TFPI‑2 expression and clinical parameters, including 5‑year overall survival, except for the patient age. In conclusion, we identified TFPI‑2 expression in the nucleus, cytoplasm and extracellular matrix in OCCC tissues. The high specificity of TFPI‑2 may support its use for diagnosis of OCCC in combination with existing markers.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	World Health Organization, International Agency for Research on Cancer, Cancer Fact Sheets. http://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf2018 4–September. 2020
3	Soslow RA: Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol. 27:161–174. 2008.PubMed/NCBI
4	Machida H, Matsuo K, Yamagami W, Ebina Y, Kobayashi Y, Tabata T, Kanauchi M, Nagase S, Enomoto T and Mikami M: Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study. Gynecol Oncol. 153:589–596. 2019. View Article : Google Scholar : PubMed/NCBI
5	Lee AW, Navajas EE and Liu L: Clear differences in ovarian cancer incidence and trends by ethnicity among Asian Americans. Cancer Epidemiol. 61:142–149. 2019. View Article : Google Scholar : PubMed/NCBI
6	Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA and Aghajanian CA: Ovarian clear cell carcinoma, outcomes by stage: The MSK experience. Gynecol Oncol. 139:236–241. 2015. View Article : Google Scholar : PubMed/NCBI
7	Anglesio MS, Carey MS, Köbel M, Mackay H and Huntsman DG; Vancouver Ovarian Clear Cell Symposium Speakers, : Clear cell carcinoma of the ovary: A report from the first ovarian clear cell symposium, June 24th, 2010. Gynecol Oncol. 121:407–415. 2011. View Article : Google Scholar : PubMed/NCBI
8	Meyer T and Rustin GJ: Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 82:1535–1538. 2000.PubMed/NCBI
9	Kudoh K, Kikuchi Y, Kita T, Tode T, Takano M, Hirata J, Mano Y, Yamamoto K and Nagata I: Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. Gynecol Obstet Invest. 47:52–57. 1999. View Article : Google Scholar : PubMed/NCBI
10	Sierko E, Wojtukiewicz MZ and Kisiel W: The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost. 33:653–659. 2007. View Article : Google Scholar : PubMed/NCBI
11	Miyagi Y, Koshikawa N, Yasumitsu H, Miyagi E, Hirahara F, Aoki I, Misugi K, Umeda M and Miyazaki K: cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: Identification as placental protein 5 and tissue factor pathway inhibitor-2. J Biochem. 116:939–942. 1994. View Article : Google Scholar : PubMed/NCBI
12	Rao CN, Reddy P, Liu Y, O'Toole E, Reeder D, Foster DC, Kisiel W and Woodley DT: Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. Arch Biochem Biophys. 335:82–92. 1996. View Article : Google Scholar : PubMed/NCBI
13	Ogawa M, Yanoma S, Nagashima Y, Okamoto N, Ishikawa H, Haruki A, Miyagi E, Takahashi T, Hirahara F and Miyagi Y: Paradoxical discrepancy between the serum level and the placental intensity of PP5/TFPI-2 in preeclampsia and/or intrauterine growth restriction: Possible interaction and correlation with glypican-3 hold the key. Placenta. 28:224–232. 2007. View Article : Google Scholar : PubMed/NCBI
14	Karaszi K, Szabo S, Juhasz K, Kiraly P, Kocsis-Deak B, Hargitai B, Krenacs T, Hupuczi P, Erez O, Papp Z, et al: Increased placental expression of placental protein 5 (PP5)/tissue factor pathway inhibitor-2 (TFPI-2) in women with preeclampsia and HELLP syndrome: Relevance to impaired trophoblast invasion? Placenta. 76:30–39. 2019. View Article : Google Scholar : PubMed/NCBI
15	Rao CN, Lakka SS, Kin Y, Konduri SD, Fuller GN, Mohanam S and Rao JS: Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin Cancer Res. 7:570–576. 2001.PubMed/NCBI
16	Rollin J, Iochmann S, Bléchet C, Hubé F, Régina S, Guyétant S, Lemarié E, Reverdiau P and Gruelet Y: Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer. 92:775–783. 2005. View Article : Google Scholar : PubMed/NCBI
17	Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR and Gogginset M: Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene. 24:850–858. 2005. View Article : Google Scholar : PubMed/NCBI
18	Guo H, Lin Y, Zhang H, Liu J, Zhang N, Li Y, Kong D, Tang Q and Ma D: Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol Biol. 8:1102007. View Article : Google Scholar : PubMed/NCBI
19	Nobeyama Y, Okochi-takada E, Furuta J, Miyagi Y, Kikuchi K, Yamamoto A, Nakanishi Y, Nakagawa H and Ushijima T: Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer. 121:301–307. 2007. View Article : Google Scholar : PubMed/NCBI
20	Wong C, Ng Y, Lee JM, Wong CC, Cheung O, Chan C, Tung EK, Ching Y and Ng IO: Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology. 45:1129–1138. 2007. View Article : Google Scholar : PubMed/NCBI
21	Xu Y, Qin X, Zhou J, Tu Z, Bi X, Li W, Fan X and Zhang Y: Tissue factor pathway inhibitor-2 inhibits the growth and invasion of hepatocellular carcinoma cells and is inactivated in human hepatocellular carcinoma. Oncol Lett. 2:779–783. 2011.PubMed/NCBI
22	Lavergne M, Jourdan ML, Blechet C, Guyetant S, Pape AL, Heuze-Vourc'h N, Courty Y, Lerondel S, Sobilo J, Iochmann S and Reverdiau P: Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer. FEBS Open Bio. 3:291–301. 2013. View Article : Google Scholar : PubMed/NCBI
23	Kempaiah P, Chand HS and Kisiel W: Human tissue factor pathway inhibitor-2 is internalized by cells and translocated to the nucleus by the importin system. Arch Biochem Biophys. 482:58–65. 2009. View Article : Google Scholar : PubMed/NCBI
24	Wang G, Zeng Y, Chen S, Li D, Li W, Zhou Y, Singer RH and Gu W: Localization of TFPI-2 in the nucleus modulates MMP-2 gene expression in breast cancer cells. Sci Rep. 7:135752017. View Article : Google Scholar : PubMed/NCBI
25	Arakawa N, Miyagi E, Nomura A, Morita E, Ino Y, Ohtake N, Miyagi Y, Hirahara F and Hirano H: Secretome-Based identification of TFPI2, A novel serum biomarker for detection of ovarian clear cell adenocarcinoma. J Proteome Res. 12:4340–4350. 2013. View Article : Google Scholar : PubMed/NCBI
26	Arakawa N, Kobayashi H, Yonemoto N, Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y, Hirahara F, et al: Clinical significance of tissue factor pathway inhibitor 2, a serum biomarker candidate for ovarian clear cell carcinoma. PLoS One. 11:e01656092016. View Article : Google Scholar : PubMed/NCBI
27	Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, et al: Association between endometriosis and risk of histological subtypes of ovarian cancer: A pooled analysis of case-control studies. Lancet Oncol. 13:385–394. 2012. View Article : Google Scholar : PubMed/NCBI
28	Cinti S, Matteis RD, Picó C, Ceresi E, Obrador A, Maffeis C, Oliver J and Palou A: Secretory granules of endocrine and chief cells of human stomach mucosa contain leptin. Int J Obes Relat Metab Disord. 24:789–793. 2000. View Article : Google Scholar : PubMed/NCBI
29	Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Störkel S, et al: EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol. 13:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
30	Wojtukiewicz MZ, Sierko E, Zimnoch L, Kozlowski L and Kisiel W: Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost. 90:140–146. 2003. View Article : Google Scholar : PubMed/NCBI
31	Altmäe S, Salumets A, Bjuresten K, Kallak TK, Wånggren K, Landgren BM, Hovatta O and Stavreus-Evers A: Tissue factor and tissue factor pathway inhibitors TFPI and TFPI2 in human secretory endometrium-possible link to female infertility. Reprod Sci. 18:666–678. 2011. View Article : Google Scholar : PubMed/NCBI
32	Zhai LL, Cai CY, Wu Y and Tang ZG: Correlation and prognostic significance of MMP-2 and TFPI-2 differential expression in pancreatic carcinoma. Int J Clin Exp Pathol. 8:682–691. 2015.PubMed/NCBI
33	Xu C, Wang H, He H, Zheng F, Chen Y, Zhang J, Lin X, Ma D and Zhang H: Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer. BMC Cancer. 13:1182013. View Article : Google Scholar : PubMed/NCBI
34	Sprecher CA, Kisiel W, Mathewes S and Foster DC: Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA. 91:3353–3357. 1994. View Article : Google Scholar : PubMed/NCBI
35	Wang G, Huang W, Li W, Chen S, Chen W, Zhou Y, Peng P and Gu W: TFPI-2 suppresses breast cancer cell proliferation and invasion through regulation of ERK signaling and interaction with actinin-4 and myosin-9. Sci Rep. 8:144022018. View Article : Google Scholar : PubMed/NCBI
36	Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA and Gilks CB: A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol. 33:14–21. 2009. View Article : Google Scholar : PubMed/NCBI
37	Huang W, Cheng X, Ji J, Zhang J and Li Q: The application value of HNF-1β transcription factor in the diagnosis of ovarian clear cell carcinoma. Int J Gynecol Pathol. 35:66–71. 2016. View Article : Google Scholar : PubMed/NCBI
38	Yamashita Y, Nagasaka T, Naiki-Ito A, Sato S, Suzuki S, Toyokuni S, Ito M and Takahashi S: Napsin A is a specific marker for ovarian clear cell adenocarcinoma. Mod Pathol. 28:111–117. 2015. View Article : Google Scholar : PubMed/NCBI
39	Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T and Fukayama M: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol. 22:824–832. 2009. View Article : Google Scholar : PubMed/NCBI
40	The Human Protein Atlas: TFPI2. https://www.proteinatlas.org/ENSG00000105825-TFPI2April 8–2020
41	Vadivel K, Ponnuraj SM, Kumar Y, Zaiss AK, Bunce MW, Camire RM, Wu L, Evseenko D, Herschman HR, Bajaj MS and Bajaj SP: Platelets contain tissue factor pathway inhibitor-2 derived from megakaryocytes and inhibits fibrinolysis. J Biol Chem. 289:31647–31661. 2014. View Article : Google Scholar : PubMed/NCBI
42	Rao CN, Cook B, Liu Y, Chilukuri K, Stack MS, Foster DC, Kisiel W and Woodley DT: HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Int J Cancer. 76:749–756. 1998. View Article : Google Scholar : PubMed/NCBI
43	Jin M, Udagawa K, Miyagi E, Nakazawa T, Hirahara F, Yasumitsu H, Miyazaki K, Nagashima Y, Aoki I and Miyagi Y: Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo. Gynecol Oncol. 83:325–333. 2001. View Article : Google Scholar : PubMed/NCBI